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Abstract
Background: Survivin is a dual function protein. It inhibits the apoptosis of cells by inhibiting caspases, and also
promotes cell growth by stabilizing microtubules during mitosis. Over-expression of survivin has been demonstrated to
induce drug-resistance to various chemo-therapeutic agents such as cisplatin (DNA damaging agent) and paclitaxel
(microtubule stabilizer) in cancers. However, survivin-induced resistance to microtubule de-stabilizers such as Vinca
alkaloids and Combretastatin A-4 (CA-4)-related compounds were seldom demonstrated in the past. Furthermore, the
question remains as to whether survivin plays a dominant role in processing cytokinesis or inhibiting caspases activity in
cells treated with anti-mitotic compounds. The purpose of this study is to evaluate the effect of survivin on the resistance
and susceptibility of human cancer cells to microtubule de-stabilizer-induced cell death.
Results: BPR0L075 is a CA-4 analog that induces microtubule de-polymerization and subsequent caspase-dependent
apoptosis. To study the relationship between the expression of survivin and the resistance to microtubule de-stabilizers,
a KB-derived BPR0L075-resistant cancer cell line, KB-L30, was generated for this study. Here, we found that survivin was
over-expressed in the KB-L30 cells. Down-regulation of survivin by siRNA induced hyper-sensitivity to BPR0L075 in KB
cells and partially re-stored sensitivity to BPR0L075 in KB-L30 cells. Western blot analysis revealed that down-regulation
of survivin induced microtubule de-stabilization in both KB and KB-L30 cells. However, the same treatment did not
enhance the down-stream caspase-3/-7 activities in BPR0L075-treated KB cells. Translocation of a caspase-independent
apoptosis-related molecule, apoptosis-inducing factor (AIF), from cytoplasm to the nucleus was observed in survivin-
targeted KB cells under BPR0L075 treatment.
Conclusion: In this study, survivin plays an important role in the stability of microtubules, but not with caspases
inhibition. Over-expression of survivin counteracts the therapeutic effect of microtubule de-stabilizer BPR0L075
probably by stabilizing tubulin polymers, instead of the inhibition of caspase activity in cancer cells. Besides microtubule-
related caspase-dependent cell death, caspase-independent mitotic cell death could be initiated in survivin/BPR0L075
combination treatments. We suggest that combining microtubule de-stabilizers with a survivin inhibitor may attribute to
a better clinical outcome than the use of anti-mitotic monotherapy in clinical situations.
Published: 3 July 2009
Molecular Cancer 2009, 8:43 doi:10.1186/1476-4598-8-43
Received: 27 March 2009
Accepted: 3 July 2009
This article is available from: http://www.molecular-cancer.com/content/8/1/43
© 2009 Cheung et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
Page 2 of 15
(page number not for citation purposes)
Background
Microtubules are protein filaments of cytoskeleton com-
posed of α-tubulin and β-tubulin molecules [1,2]. In cells,
microtubule filaments rapidly alternate between phases of
growth and shrinkage (dynamic instability) during cell
cycle. Since microtubules play crucial roles in the regula-
tion of the mitotic apparatus, disruption of microtubules
can induce cell cycle arrest in M phase, the formation of
abnormal mitotic spindles, and final triggering of signals
for apoptosis. The discovery that the cytotoxic activity of
various compounds is through interference with the
mitotic spindle apparatus has attracted much attention
within the past two decades, and microtubules have
become an attractive pharmacologic target for anticancer
drug discovery [3,4]. Anti-mitotic compounds such as vin-
cristine, vinblastine (microtubule-destabilizing Vinca
alkaloid) and paclitaxel (microtubule-stabilizing taxane)
have been developed to target cancers clinically [5-7].
Although the taxanes and Vinca alkaloids are effective for
the management of different malignancies, their potential
is limited by the development of multidrug resistance
(MDR) [8,9]. MDR is multi-factorial, with one pathway
leading to resistance mediated by over-expression of
transmembrane efflux pumps, namely, the Mr 170,000 P-
glycoprotein (P-gp170/MDR) and multidrug resistance
protein (MRP) [10]. Therefore, there has been great inter-
est in identifying novel microtubule inhibitors that can
overcome various modes of resistance and have improved
pharmacology profiles.
BPR0L075 [6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-
1H-indole] is a novel synthetic compound discovered
through research to identify new microtubule inhibitors
in our laboratory. It is a heterocyclic Combretastatin A-4
(CA-4) analog, which is derived from the South African
tree Combretum caffrum, and inhibits tubulin polymeriza-
tion by binding to tubulin at the colchicine-binding site
[11,12]. Unlike traditional microtubule inhibitors such as
vincristine and paclitaxel, BPR0L075 is effective in sup-
pressing cell growth of both MDR-positive and -negative
tumor cell lines [12]. BPR0L075 also induces microtubule
de-stabilization-related downstream processes such as
phosphorylation of Bcl-2 and activation of caspase-3 [12].
In-vivo, BPR0L075 shows potent activity against the
growth of xenograft tumors of the gastric carcinoma
MKN-45, human cervical carcinoma KB, and KB-derived
P-gp170/MDR-overexpressing KB-VIN10 cells in nude
mice [12]. Although BPR0L075 is a promising anticancer
compound that can be applied to the management of var-
ious malignancies, particularly for patients with MDR-
related drug resistance, its effectiveness in patients with
MDR-unrelated drug resistance is still unknown.
Survivin is a member of the inhibitors of apoptosis (IAPs).
Other than the expression of MDR, expression of survivin
has been related to the causation of cancer-drug resistance
in various studies [13-15]. At the molecular level, survivin
is a bifunctional protein that acts as a suppressor of apop-
tosis and plays a central role in cell division. It has been
suggested that survivin, possibly the mitochondrial frac-
tion instead of the cytosol fraction, inhibits apoptosis
through interference with caspases [16-18]. A study using
surface plasmon resonance spectroscopy showed that sur-
vivin directly binds to caspase-3 and caspase-7 with
nanomolar affinity [16]. In confirmation, myc-tagged sur-
vivin bound caspase-3 and caspase-7 in immunoprecipi-
tation studies [16]. Survivin also promotes cell survival
through interference with cell cycle-related kinases and
microtubule networks. Survivin binds to centromeres on
a para-polar axis during prophase/metaphase, relocates to
the spindle midzone during anaphase/telophase, and dis-
appears at the end of telophase [19]. Over-expression of
survivin reduced centrosomal microtubule nucleation
and suppressed both microtubule dynamics instability in
mitotic spindles and bidirectional growth of microtubules
in midbodies during cytokinesis [20]. In addition, it has
been shown that intracellular loading of a polyclonal anti-
body to survivin induced microtubule defects and
resulted in formation of multipolar mitotic spindles [21].
Although over-expression of survivin has been suggested
to cause resistance to various chemotherapeutic com-
pounds in cancers, survivin-induced resistance to micro-
tubule de-stabilizers such as Vinca  alkaloids and
cochicine-related compounds in cancers was seldom dem-
onstrated in the past [22]. Furthermore, the question
remains as to whether survivin plays a dominant role in
processing cytokinesis or inhibiting caspases activity in
cells treated with anti-mitotic compounds. In fact, down-
regulation of survivin did not induce massive cell death in
HeLa cells [23]. However the process of cytokinesis was
heavily impaired by the same treatment [23]. In this
study, we have generated a microtubule de-stabilizer
BPR0L075-resistant cell line and shown for the first time
that down-regulation of survivin enhances sensitivity to
the microtubule de-stabilizing compound BPR0L075. We
further describe the role of survivin in interfering sensitiv-
ity to the microtubule de-stabilizer, BPR0L075, in human
oral carcinoma cells.
Results
Over-expression of survivin in both BPR0L075/colchicine-
treated cancer cells and BPR0L075-resistant cancer cells
Over-expression of survivin in response to anti-cancer
treatments has been demonstrated previously [24]. Here,
we examined the level of survivin expression in response
to BPR0L075 treatment in various cancer cell lines.
Human p53-wildtype KB and p53-mutated HONE-1 can-
cer cell lines were used in this study. Cells were treated
with 8 nM (IC50 value) of BPR0L075 for 24 h. Cell lysate
was extracted and the expressions of various intracellular
proteins were analyzed by western blotting. A time-
dependent phosphorylation of Bcl2 in KB cells was shownMolecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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and this result was consistent with our previously pub-
lished data (Figure 1A) [12]. Both un-treated cell lines
expressed survivin endogenously (Figure 1A). In addition,
the treatment of BPR0L075 (8 nM) induced over-expres-
sion of survivin in a time-dependent manner in both can-
cer cell lines (Figure 1A). Surprisingly, over-expression of
a survivin negative-regulator, p53, in response to
BPR0L075 was also observed in KB cells in a time-depend-
ent manner (Figure 1A).
KB cells were chosen for further in vitro investigation, con-
sidering that the same cell line was chosen in our previ-
ously published report [12]. To determine whether over-
expression of survivin was unique to BPR0L075 treat-
ment, KB cells were treated with 10 nM (IC50 value) of col-
chicine (microtubule destabilizer) and intracellular
proteins were analyzed by western blotting. Cells incu-
bated with colchicine also induced over-expression of sur-
vivin in a time-dependent manner (Figure 1A, bottom
panel). FACS analysis was performed to determine
whether BPR0L075-induced over-expression of survivin
was caused by cell cycle arrest at the G2/M phase. KB cells
were treated with various concentrations of BPR0L075 for
24 h and nucleus was stained with propidium iodide.
Although high concentrations (≥ 16 nM, 2 × IC50) of
BPR0L075 induced G2/M arrest, FACS analysis clearly
showed no difference in the percentage of G2/M popula-
tion between untreated-cells and cells treated with 8 nM
(IC50 value) of BPR0L075 (Additional file 1).
To determine whether BPR0L075-induced over-expres-
sion of survivin in KB cells was caused by changes in the
rate of survivin gene transcription, RT-PCR was per-
formed. As was observed for the protein, the level of sur-
vivin mRNA transcripts was increased by approximately 3-
fold in KB cells after 24 h of BPR0L075 incubation (Figure
1B). It has been suggested that p53 down-regulates the
expression survivin [25]. To determine whether p53 plays
a role in the BPR0L075-induced over-expression of sur-
vivin in KB cells, a p53 inhibitor pifithrin-α was used.
Interestingly, western blot analysis revealed that co-incu-
bation pifithrin-α was unable to increase the level of sur-
vivin expression in BPR0L075-treated KB cells (Figure
1C). Taken together, these results suggest that p53-ind-
pendent over-expression of survivin may affect cancer
cells susceptibility to BPR0L075-induced cytotoxicity.
A KB-derived BPR0L075-resistant cancer cell line, KB-L30,
was recently generated in our laboratory. This drug-resist-
ant cell line was shown to withstand 30 nM of BPR0L075
under culturing condition (data not shown). In addition,
this specific cell line showed resistance to colchicine in
vitro (data not shown). Under BPR0L075-free conditions,
western blot analysis revealed that the baseline expression
of survivin was increased by approximate 2.3-fold in KB-
L30 cells, as compared to the drug-sensitive KB cells (Fig-
ure 1D). Real-time PCR also revealed that the level of sur-
vivin mRNA transcripts was significantly increased by
approximate 80% (*p < 0.01) in the KB-L30, as compared
to its drug-sensitive parental cells (Figure 1E). FACS anal-
ysis was performed to determine whether over-expression
of survivin in KB-L30 was caused by cell cycle arrest at the
G2/M phase. KB and KB-L30  cells cultured under
BPR0L075-free coditions were stained with propidium
iodide. FACS analysis clearly showed no significant differ-
ence in the percentage of G2/M population between KB
(16.3%) and KB-L30  (16.5%) cells (Additional file 1).
Taken together, the detection of high levels of survivin in
the BPR0L075-resistant KB-L30 cells suggests that intracel-
lular survivin may affect cancer cells susceptibility to
BPR0L075-induced cytotoxicity.
Down-regulation of survivin increases sensitivity to 
BPR0L075 and colchicine in cancer cells
To investigate the sensitivity of cancer cells to the micro-
tubule de-stabilizer, BPR0L075, after inhibition of sur-
vivin, siRNA was applied to down-regulate survivin in
cancer cell lines, and the level of cell viability was exam-
ined. Cells were transfected with validated-siRNA oligom-
ers, siR-C (scramble control) or siR-S (survivin specific) by
liposomal reagent. Down-regulation of survivin mRNA
transcripts by siRNA in both KB and KB-L30 cells after 36
h of transfection was confirmed by RT-PCR (Fig. 2A). Suc-
cessful down-regulation of survivin protein by siR-S after
48 h of transfection was shown by immunofluorescence
microscopy (Figure 2B). Western blot analysis further
confirmed that survivin protein levels were successfully
down-regulated after 48 h of siRNA transfection (Figure
2C).
Morphologically, the survivin-targeted KB cells became
round and slightly enlarged in size (Figure 3A). Although
down-regulation of survivin by siR-S induced morpholog-
ical changes in KB cells under BPR0L075-free conditions
(Figure 3A), the same treatment did not reduce cell viabil-
ity (Figure 3B). Interestingly, down-regulation of survivin
by siR-S enhanced the sensitivity to BPR0L075 in KB cells
in vitro. Co-treatment of siR-S and BPR0L075 significantly
reduced cell viability of KB by 17–31% among various
concentrations of BPR0L075 in vitro as compared to the
drug alone treatment (Figure 3B).
We further examined the possibility of restoring the sensi-
tivity to BPR0L075 by down-regulation of survivin in KB-
L30  cells. Phase contrast microscopy and cell viability
studies showed that down-regulation of survivin did not
induce KB-L30 cells cell death under BPR0L075-free con-
ditions (Figure 3C and 3D). In contrast, down-regulation
of survivin by siR-S induced massive cell death in KB-L30
cancer cells under normal culture conditions (30 nM of
BPR0L075) (Figure 3C and 3D). Co-treatment of siR-S
and BPR0L075 reduced the viability of KB-L30 cells byMolecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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BPR0L075 induces over-expression of survivin in human KB and HONE-1 cancer cells Figure 1
BPR0L075 induces over-expression of survivin in human KB and HONE-1 cancer cells. (A) Cells were treated with 
8 nM of BPR0L075 and 10 nM of colchicine for 6 h, 12 h and 24 h. Cell lysate were extracted and proteins were resolved by 
SDS-PAGE. Western blot analysis was performed as described in Materials and Methods. (B) KB cells were treated with 8 nM 
of BPR0L075 for 24 h and total RNA was extracted. Level of survivin mRNA was determined by RT-PCR. GAPDH was 
included for the use of semi-quantization. Relative band intensity was shown. (C) KB cells were incubated with 8 nM of 
BPR0L075 for 24 h with/without pifithrin-α pre-incubation. Cell lysate were extracted and proteins were resolved by SDS-
PAGE. Western blot analysis was performed as described in Materials and Methods. Relative band intensity was shown. (D) 
KB-L30 cells over-expresses survivin. Total cell lysate of KB and K-L30 cells was extracted and proteins were resolved by SDS-
PAGE. Western blot analysis was performed as described in Materials and Methods. Relative band intensity was shown. (E) 
Total mRNA of KB and KB-L30 cells was extracted. Level of survivin mRNA was determined by real-time PCR. Relative sur-
vivin to GAPDH ratios were shown. A statistically significant difference in the level of survivin mRNA between KB and KB-L30 
cells is denoted by "*", (p < 0.001).Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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20–52% among various concentrations of BPR0L075 in
vitro as compared to the drug alone treatment (Figure 3D).
We have previously demonstrated that colchicine induced
over-expression of survivin in KB cells (Figure 1A). To
determine whether down-regulation of survivin by siRNA
also increases the sensitivity to colchcine in KB and KB-
L30 cells, cells co-treated with siR-C/siR-S and colchicine
were analyzed by cell viability assay. Interestingly, down-
regulation of survivin by siR-S enhanced the sensitivity to
colchicine in both KB and KB-L30 cells in vitro (Figure 3E).
Taken together, our results indicate that survivin plays an
important role in the sensitivity to microtubule de-stabi-
lizers, BPR0L075 and colchicine, in both KB and KB-L30
cells.
Survivin interferes with microtubule dynamics
BPR0L075-induced de-stabilization of microtubule has
been shown in cancer cells [12]. On the other hand, stabi-
lization of microtubule networks has been suggested to
induce drug-resistance of tubulin de-stabilizating agents
in HUVEC cells [26]. Therefore, microtubule polymeriza-
tion status was investigated to determine whether survivin
counteracts the effectiveness of BPR0L075 by interfering
with the microtubule dynamics in KB cancer cells. Soluble
and insoluble fractions of the cell lysate were extracted.
Interestingly, survivin was not detected in the soluble frac-
tion of both cell lines (Figure 4A). The amount of insolu-
ble survivin in KB-L30 was increased by approximately
2.2-fold as compared to the BPR0L075-sensitive KB cells.
In correlation, the amounts of insoluble α – and β-tubulin
were also increased in KB-L30 cells (Figure 4A). In con-
trast, the amounts of soluble α – and β-tubulin were
decreased in KB-L30 cells (Figure 4A). These results reveal
a positive correlation between the expression of survivin
and stabilization of microtubule.
Interaction between survivin expression and dynamic for-
mation of the microtubule was shown by western blot
analysis. Down-regulation of survivin by siR-S reduced
the amount of insoluble α-tubulin in both KB and KB-L30
cells (Figure 4B and 4C). However, the same treatment did
Down-regulation of survivin in KB and KB-L30 cells by siRNA Figure 2
Down-regulation of survivin in KB and KB-L30 cells by siRNA. (A) Cells were seeded on 24-well plates overnight and 
transfected with siR-C (scramble control) or siR-S (survivin specific) for 36 h. Total RNA was extracted by Trizol reagent. RT-
PCR was performed and PCR products were resolved by DNA electrophoresis. GAPDH was used as an internal control (B) 
Cells were seeded on 8-well chamber slides overnight and transfected with siR-C (scramble control) or siR-S (survivin specific) 
for 48 h. Cells were labeled with FITC-coupled anti-human survivin antibody and counter-stained with DAPI nucleus stain. 
Slides were analyzed using fluorescent microscopy. (C) Cells were seeded on 6-well plates overnight and transfected with siR-
C or siR-S for 48 h. Cell lysate were extracted and proteins were resolved by SDS-PAGE. Western blot analysis was per-
formed as described in Materials and Methods.Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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Down-regulation of survivin increases sensitivity to BPR0L075 and colchicine in KB and KB-L30 cells Figure 3
Down-regulation of survivin increases sensitivity to BPR0L075 and colchicine in KB and KB-L30 cells. KB and KB-
L30 cells were seeded on 96-well plates overnight. Cells were pre-transfected with siR-C (scramble control) or siR-S (survivin 
specific) for 24 h and incubated with various concentrations of BPR0L075 for 48 h. Cells were analyzed by (A and C) phase-
contrast microscopy and (B and D) MTT cell viability assay. Mean differences in cell viability between treatments at same dose 
of BPR0L075 were labeled on the graph. (E) KB and KB-L30 cells were transfected with siR-C (scramble control) or siR-S (sur-
vivin specific) for 24 h and incubated with 10 nM (IC50 value, KB) and 70 nM (IC50 value, KB-L30) of colchicine for 48 hours. 
Cells were analyzed by MTT cell viability assay. A statistically significant difference in the level of viability between cells treated 
with siR-S/BPR0L075 combination therapy and BPR0L075 monotherapy is denoted by "*", (p < 0.001).Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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Down-regulation of survivin changes the dynamics of microtubule networks Figure 4
Down-regulation of survivin changes the dynamics of microtubule networks. (A) Supernatant and pellet fractions of 
un-treated KB and KB-L30 cells were extracted. Proteins were resolved by SDS-PAGE and analyzed by western blotting. Anti-
actin was used as an internal control. Relative band intensities were shown. (B and C) KB and KB-L30 cells were transfected 
with siR-C (scramble control) and siR-S (survivin specific) for 48 h. Total lysate and pellet fractions of cells were extracted. 
Proteins were resolved by SDS-PAGE and analyzed by western blotting. Anti-actin was used as an internal control. Relative 
band intensity was shown. (D) Down-regulation of survivin reduced tubulin acetylation in KB and KB-L30 cells. Cells were 
transfected with siR-C or siR-S for 24 h and co-incubated with/without 8 nM (KB) and 70 nM (KB-L30) of BPR0L075 for 48 h. 
Total cell lysate of cells was extracted. Proteins were resolved by SDS-PAGE and analyzed by western blotting. Anti-actin was 
used as an internal control. (E) Down-regulation of survivin destabilizes the microtubule networks. KB cells were seeded on 8-
well chamber slides. Cells were pre-transfected with siR-C (scramble control) or siR-S (survivin specific) for 24 h and co-incu-
bated with 4 nM of BPR0L075 for 24 h. Cells were fixed and labeled with mouse anti-human α-tubulin antibody and FITC-cou-
pled anti-mouse secondary antibody. Slides were analyzed by fluorescent microscopy.Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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not induce any changes in the general expression of α-
tubulin (Figure 4B and 4C). Tubulin acetylation is consid-
ered to be a marker of microtubule stabilization [27,28].
In our study, western blot analysis revealed that down-reg-
ulation of survivin by siR-S reduced the amount of intrac-
ellular acetylated α-tubulin in both KB and KB-L30 cells,
as compared to siR-C treated control. The combination of
siR-S and 8 nM of BPR0L075 further reduced the amount
of acetylated α-tubulin, as compared to siR-S and drug
alone treatment in KB cells (Figure 4D, top panel). In
addition, combination of siR-S and 70 nM of BPR0L075
also reduced the amount of acetylated α-tubulin, as com-
pared to siR-S and drug alone treatment in KB-L30 cells
(Figure 4D, bottom panel). Immunofluorescent micros-
copy was used to provide visualization of the microtubule
networks in cells. Untreated KB cells showed intact micro-
tubule networks (Figure 4E). In contrast, down-regulation
of survivin by siR-S induced disorganization of the micro-
tubule networks (Figure 4E). Furthermore, the combina-
tion of siR-S and 4 nM of BPR0L075 induced synergistic
microtubule depolarization and changes in cell morphol-
ogy (Figure 4E). These results indicate that survivin stabi-
lizes the microtubule networks and possibly counteracts
the therapeutic effect of microtubule de-stabilizer,
BPR0L075, by stabilizing tubulin polymers.
Inhibition of survivin enhances sensitivity to BPR0L075 via 
caspase-3/-7 dependent/independent mechanisms
BPR0L075-induced microtubule de-stabilization and sub-
sequent activation of caspase-3 has been shown in KB
cells previously [12]. Here, real-time caspase-3/-7 activity
imaging was performed to determine whether de-stabili-
zation of the microtubule networks by targeting survivin
enhances the sensitivity to BPR0L075 in cancer cells via
downstream caspase-3/-7 activations. Cells pre-trans-
fected with siR-C and siR-S were incubated with
BPR0L075 for various durations. The activities of cas-
pases-3/-7 were measured with the MagicRed™ real-time
caspase-3/-7 detection kit, and nuclei were counter-
stained blue with a Hoechst dye.
In BPR0L075-free conditions, caspase-3/-7 activities were
not detected in both cell lines (Figure 5A and 5B). KB-L30
cells were normally cultured in media with the presence of
BPR0L075 (30 nM). In this condition, caspase-3/-7 activ-
ities were also not detected (Figure 5B, middle row). In
contrast, high dose of BPR0L075 induced caspase-3/-7
activity in both KB (8 nM, IC50 value) and KB-L30 (70 nM,
IC50 value) cells, as indicated by red fluorescence staining
of the cytoplasm of cells (Figure 5A and 5B). Inhibition of
survivin by siR-S did not induce caspase-3/-7 activities in
both cell lines under drug-free conditions (Figure 5A and
5B). In addition, co-treatment of siR-S and 4 nM of
BPR0L075 did not enhance caspase-3/-7 activities in KB
cells, as compared to the BPR0L075 monotherapy at vari-
ous time points (Figure 5C). Interestingly, down-regula-
tion of survivin induced caspase-3/-7 activities in
BPR0L075-cotreated KB-L30  cells (Figure 5B, middle
row). Therefore, our results indicate that survivin directly
or indirectly interferes with the caspase-3/-7 in KB-L30,
but not in KB cells during BPR0L075 treatments.
Activation of caspase-3/-7 induces DNA fragmentation
[29,30]. Nucleus degradation was observed with KB cells
treated with 16 nM (twice of IC50 value) of BPR0L075
after 72 h (data not shown). Here, massive nucleus degra-
dation was observed in the siR-S/BPR0L075-cotreated KB-
L30  cells (Figure 5B, white arrows). In contrast, intact
nucleus was shown in the drug alone treatment (Figure
5B). Although caspase-3/-7 activities were not increased in
the combination treatment, increased degradation of
nucleus was shown in KB cells, as compared to the drug
alone treatment (Figure 5A, white arrows). The early
appearance of DNA fragmentation in KB cells under com-
bination treatment was further confirmed by TUNEL assay
(Figure 5D).
Down-regulation of survivin induces translocation of 
apoptosis-inducing factor in KB cells
DNA fragmentation can be induced by caspase-independ-
ent mechanisms. Apoptosis-inducing factor (AIF) is a pro-
tein which induces large-scale DNA fragmentation during
caspase-independent apoptosis [31,32]. The possibility
that siRNA-mediated down-regulation of survivin would
lead to the translocation of AIF was explored. KB cells
were treated with siR-C, siR-S, or drug BPR0L075 alone,
and AIF expression was examined by immunofluores-
cence microscopy using an anti-AIF antibody. The cyto-
plasm of cells treated with siR-C for 48 h was stained green
with a ring-like pattern around the nucleus by the anti-AIF
antibody, as was the cytoplasm of cells treated with
BPR0L075 (Figure 6). In marked contrast, it was the
nucleus that was stained green by the anti-AIF antibody in
cells treated with the siR-S against survivin, suggesting that
AIF translocated from cytoplasm to the nucleus when sur-
vivin was targeted with siRNA (Figure 6). Cells treated
with a combination of siR-S and BPR0L075 induced sim-
ilar phenotype to siR-S mono-treatment (Figure 6). Thus,
caspase-independent cell death could be induced by
down-regulation of survivin in KB cells.
Discussion
Studies suggest that survivin contributes to chemo-resist-
ance and enhances cell survival through two potential
mechanisms: 1) the inhibition of apoptosis by blocking
activated caspases [18,22], and 2) by stabilizing the
microtubule network to avert cell catastrophe [33]. These
two mechanisms exert different weights in the contribu-
tion to cancer cell survival, depending on the therapeutic
agent used and possibly the cancer type. For example, in
lung cancer, Normura et al. demonstrated that inhibition
of apoptosis mediated by survivin contributed to cispla-Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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tin-resistance [34]. In another study, Zhang et al. showed
that that adenovirus-mediated inhibition of survivin
expression actually sensitized human prostate cancer cells
to paclitaxel [35]. Their studies also suggested that sur-
vivin mediates resistance to paclitaxel through suppres-
sion of caspase-mediated apoptosis [15]. However,
another study revealed that survivin is required for stable
checkpoint activation in paclitaxel-treated HeLa cells [23].
Down-regulation of survivin by siRNA abrogated the abil-
ity of cells to sustain paclitaxel-induced mitotic arrest
[23]. In addition, down-regulation of survivin alone did
not induce massive death in HeLa cells [23]. Therefore,
question remains as to whether survivin plays a dominant
role in processing cytokinesis or inhibiting caspases activ-
ity in cells treated with anti-mitotic compounds. Interest-
ingly, survivin-induced resistant to microtubule de-
stabilizers such as Vinca alkalodis, cochicine and Combre-
tastatin A-4 related compounds in cancers was rarely dem-
onstrated in the past [22]. In our study, we found that
survivin counteracts the therapeutic effect of microtubule
de-stabilizer, BPR0L075, by stabilizing tubulin polymers.
BPR0L075 is a novel anti-mitotic compound and its
mechanisms of action have been published elsewhere
[11,12]. In brief, BPR0L075 is a heterocyclic Combretasta-
tin A-4 (CA-4) analog that inhibits tubulin polymeriza-
Down-regulation of survivin with co-incubation of BPR0L075 enhances the activity of caspase-3 in KB-L30, but not KB cells Figure 5
Down-regulation of survivin with co-incubation of BPR0L075 enhances the activity of caspase-3 in KB-L30, but 
not KB cells. (A and B) KB and KB-L30 cells were seeded on 8-well chamber slides overnight. Cells were pre-transfected 
with siR-C (scramble control) or siR-S (survivin specific) for 24 h and co-incubated with various concentrations of BPR0L075. 
MagicRed™-DEVD Real-time Caspase-3/-7 Activity kit (Immunochemistry Technologies LLC) was used. Activated-caspase-3/-
7 was stained red and nucleus was counter-stained blue by Hoechst 33342. White arrows indicate cells with nucleus degrada-
tion. (C) Quantitative measurement of caspase-3/-7 activity. KB cells were seeded on 96-well plate and transfected with siR-C 
(scramble control) or siR-S (survivin specific) for 24 h. siRNA-treated cells were incubated with 4 nM of BPR0L075 for various 
times. Caspase-3/-7 activity was analyzed by the use of MagicRed™-DEVD real-time caspase-3/-7 activity kit with a 96-well 
plate-reader. (D) Analysis of DNA fragmentation by TUNEL assay. KB cells were pre-transfected with siR-C (scramble con-
trol) or siR-S (survivin specific) for 24 h and co-incubated with 4 nM of BPR0L075 for 48 h. DNA fragmentations were analyzed 
using the In Situ Cell Death Detection kit. Nucleus with DNA fragmentation was stained red.Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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tion by binding to tubulin at the colchicine-binding site
[11,12]. In the current study, up-regulation of survivin in
response to BPR0L075 was observed in both p53-wildtype
KB and p53-mutated HONE-1 cancer cells. In addition,
the baseline expression of survivin was also increased in
KB-derived BPR0L075-resistant KB-L30, as compared to
its drug-sensitive parental cells. Therefore, one important
aim of our study was to investigate whether survivin could
be potentially important in sensitivity to the microtubule-
destabilizing compound, BPR0L075, especially in
BPR0L075-resistant cancer cells. Here, we demonstrate
that down-regulation of survivin by siRNA induced hyper-
sensitivity to BPR0L075 in KB and partially restored sensi-
tivity to the drug in BPR0L075-resistant KB-L30  cells.
These results suggested for the first time that survivin plays
an important role in the sensitivity and resistant to the
microtubule de-stabilizer, BPR0L075. Furthermore, p53 is
widely believed to be a negative regulator of survivin
expression [25,36-41]. However, our current results indi-
cate that whether p53 plays a definite role in survivin reg-
ulation under various chemo-stresses remains agurable.
In our study, dose-dependent co-expression of p53 and
survivin in response to BPR0L075 was shown in p53-
wildtype KB cells. Interestingly, co-incubation of a p53-
inhibitor, pifithrin-α, was unable to increase the level of
survivin expression in BPR0L075-treated cells. In addi-
tion, over-expression of survivin in response to BPR0L075
was also observed in p53-mutated HONE-1 cells. Taken
together, our study suggested that BPR0L075 induces
overexpression of survivin through a p53-independent
pathway.
It has been reported that VEGF-induced expression of sur-
vivin preserved the microtubule integrity and stabilization
of the microtubule networks subsequently induced drug-
resistance to both CDDP and paclitaxel in HUVEC cells
[33]. A role for altered microtubule polymer levels in vin-
cristine resistance of acute lymphoblastic leukemia has
also been demonstrated in vivo [26]. In the present study,
increased tubulin polymer levels were observed in the
BPR0L075-resistant KB-L30 cells as compared to its drug-
sensitive parental cells. We also demostrated that down-
regulation of survivin de-stabilizes tubulin polymers in
both KB and KB-L30 cancer cells. In addition, the level of
acetylated  α-tubulin was synergistically reduced in the
survivin/BPR0L075 combination therapy as compared to
the monotherapy in KB cells. Thus, the over-expression of
survivin in response to the microtubule de-stabilizer
BPR0L075 reflects one of the possible cell survival mech-
anisms by stabilizing microtubule. It is also worth noting
that over-expression of survivin was observed in both col-
chicine- and vincristine-treated KB cells (data not shown).
In addition, KB-L30 cells are relatively more sensitive to
paclitaxel (microtubule stabilizer) and at the same time
more resistant to both colchicine and vincristine (micro-
tubule de-stabilizers), as compare to their parental cells
(data not shown). Interestingly, Ong et al's study also
revealed that a vincristine-resistant xenograft with high
levels of polymerized tubulin was relatively sensitive to
the microtubule-polymerizing drug paclitaxel [26].
Indeed, further investigations are needed to determine the
relationships between the survivin-interfered microtubule
dynamics and the resistance to various microtubule de-
stabilizers in depth.
Although various studies reveal that survivin interferes
with cytokinesis and inhibits caspases during apoptosis,
the question remains as to whether survivin plays a dom-
inant role in regulating cell cycle or inhibiting cell death.
In fact, down-regulation of survivin did not induce mas-
sive cell death in HeLa cells [23]. However, the process of
cytokinesis was heavily impaired by the same treatment
[23]. In the present study, down-regulation of survivin did
not induce cell death in both KB and KB-L30 cells under
BPR0L075-free conditions. In accord with the results from
cell viability study, down-regulation of survivin did not
induce caspase-3/-7 activities in both KB and KB-L30 cells
cultured under drug-free conditions. It is widely believed
Down-regulation of survivin with/without BPR0L075 induced  the translocation of AIF in KB cells Figure 6
Down-regulation of survivin with/without BPR0L075 
induced the translocation of AIF in KB cells. KB cells 
were treated with siR-C (scramble control), siR-S (survivin 
specific), 4 nM of BPR0L075 or siR-S/BPR0L075 combination 
for 72 h. AIF was detected using anti-AIF antibody and FITC-
conjugated anti-rabbit IgG antibody.Molecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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that anti-mitotic compounds induce mitotic arrest by acti-
vating the spindle checkpoint and these molecular
changes subsequently activate caspase-dependent apopto-
sis. Our previous study agreed with that hypothesis as the
microtubule de-stabilizer, BPR0L075, induced activation
of caspase-3 in various cancer cell lines [12]. Interestingly,
down-regulation of survivin did not enhance caspase-3/-7
activities in the survivin/BPR0L075 co-treated KB cells,
given that the microtubule dynamics were heavily
impaired in the same treatment. These results suggested
that survivin functions predominantly in microtubule sta-
bilization or mitotic progression, as opposed to inhibi-
tion of caspase-dependent cell death in KB cells under
BPR0L075-free conditions. However, down-regulation of
survivin induced caspase-3/-7 activities in the survivin/
BPR0L075 co-treated KB-L30  cells. Therefore, whether
survivin interferes with the caspase-3/-7 during BPR0L075
treatment seems to be cell type dependent. Furthermore,
incomplete restoration to the drug sensitivity in survivin
down-regulated KB-L30 cells indicates that other impor-
tant drug resistance mechanisms may co-exist.
As we mentioned earlier, it is believed that anti-mitotic
compounds induce mitotic arrest by activating the spindle
checkpoint and these molecular changes subsequently
activate caspase-dependent apoptosis. However, our cur-
rent study reveals that down-regulation of survivin syner-
gistically affects the microtubule dynamics and cell
viability without significant induction in caspases activity.
In addition, increased DNA fragmentation and nucleus
degradation were observed in the survivin/BPR0L075
combination treatments, as compared to the BPR0L075
monotherapy. Therefore, down-regulation of survivin
together with BPR0L075 may initiate caspase-independ-
ent DNA fragmentation and cell death in KB cells. During
one form of caspase-independent apoptosis, apoptosis-
inducing factor (AIF) translocates from the mitochondria
to the nucleus [42-44]. AIF is a flavoprotein that is nor-
mally confined to the mitochondrial intermembrane
space, but induces chromatin condensation and fragmen-
tation of DNA into high molecular weight forms of >50 kb
when it translocates to the nucleus [31,32]. It has been
suggested that survivin interferes with the translocation of
AIF. In fact, translocation of AIF from the mitochondria to
the nucleus was shown in YUSAC2 melanoma cells
treated with a cell-permeable dominant-negative survivin
protein [45]. Furthermore, involvement of AIF in nocoda-
zole (microtubule de-stabilizer)-induced caspase-inde-
pendent mitotic cell death was also demostrated
perviosuly [46]. In Niikura et al.'s study, treatment with
nocodazole or paclitaxel induced kinetochore-microtu-
bule detachement, mitotic arrest and subsequent AIF-
involved caspase-independent cell death in cancer cells
[46]. In our study, translocation of AIF from the cyto-
plasm to the nucleus following the down-regulation of
survivin indicates that survivin inhibits caspase-independ-
ent apoptosis in KB cells. Thus, both caspase-dependent
and caspase-independent DNA fragmentation could be
co-operated in KB cells during survivin-targeted
BPR0L075 combination treatments. These results sug-
gested that down-regulation of survivn together with
microtubule de-stabilizers may induces caspase-inde-
pendent mitotic cell death, possible through AIF activa-
tion. However, our study could not determine the rate of
AIF activity between survivin monotherapy and survivin/
BPR0L075 combination. Further investigation is needed
to determine the level of AIF activities between different
treatments.
Conclusion
Drug resistance is a common problem in the management
of neoplastic diseases. The effectiveness of a single anti-
cancer agent is limited by the fact that drug resistance
mechanisms can be introduced by cancer cells during cell
evolution or re-arrangement of tumor micro-environ-
ment. In clinical situations, rather than treating patients
with a single anti-cancer agent, combination therapies are
preferred. BPR0L075 is a tubulin-targeting compound
capable of inducing cytotoxic effect among various MDR-
positive/-negative cancers both in vitro and in vivo. Down-
regulation of survivin with an anti-sense survivin gene
enhances the sensitivity to the DNA damaging agent, cis-
platin, which in KB have been demonstrated both in vitro
and  in vivo previously [14]. However, the underlying
molecular mechanisms of the drug resistant to anti-
mitotic agents, especially for the microtubule de-stabiliz-
ing compounds, have not been discussed in detail. Here,
we have shown that survivin counteracts the therapeutic
effect of microtubule de-stabilizer, BPR0L075, by stabiliz-
ing tubulin polymers in human KB oral carcinoma cells.
Since survivin plays an important role in the sensitivity of
microtubule de-stabilizing agents, the use of survivin-tar-
geted agents such as oxaliplatin and SPC3042 (Santaris
Pharma) in anti-mitotic combination therapy maybe of
clinical benefit [47,48]. Also, unlike other potential ther-
apeutic targets, survivin is expressed in few adult tissues.
Thus, survivin-specific combination therapy is likely to
produce few adverse effects.
Methods
Drug
The compound BPR0L075 was synthesized at the Divi-
sion of Biotechnology and Pharmaceutical Research,
National Health Research Institutes, Zhunan, Taiwan,
ROC. BPR0L075 was obtained in 72% yield from 6-meth-
oxyindole and 3,4,5-trimethoxybenzoyl chloride. The
detailed synthetic method was previously published[11]
Cell lines, antibodies and reagents
The human oral carcinoma cells (KB) were purchased
from the American Type Culture Collection (ATCC, Man-
assas, VA). KB and human nasopharyngeal carcinomaMolecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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(HONE-1) cells were cultured in RPMI 1640 medium
(Gibco, Grand Island, NY), supplemented with 5% fetal
bovine serum, penicillin (100 U/mL), streptomycin (100
μg/mL) and L-glutamine (0.29 mg/mL), at 37°C. The
antibodies used in this study included: a mouse anti-α
Tubulin antibody (Upstate Cell signaling, Lake Placid,
NY), a mouse anti-β Tubulin antibody (BD PharMingen,
Franklin Lakes, NJ), a mouse anti-Actin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA), a rabbit anti-Sur-
vivin antibody (R&D Systems, Minneapolis, MN) and a
rabbit anti-AIF antibody (R&D Systems, Minneapolis,
MN), a mouse anti-Bcl2 antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA).
Establishment of the KB-derived BPR0L075-resistant cell 
line
Human oral carcinoma cells (KB) were cultured in RPMI
1640 medium as previously described. BPR0L075-resist-
ant cells were established from KB cells by exposure to
increasing concentrations of BPR0L075. Briefly, KB cells
were initially incubated in completed medium containing
5nM of BPR0L075 that yielded 40% cell survival for a
period of 3~4 weeks, and the cells that proliferated were
repeatedly subcultured in completed medium containing
increasing concentrations of the drug (a 20% increment
each time). Cells that grew exponentially in the presence
of 30 nM of BPR0L075 were obtained and subcloned by
dilution plating in 48-well plates. Individual clones were
isolated. For maintenance, these subclones were cultured
under conditions similar to those used for KB, except for
an addition of BPR0L075 (30 nM).
RT-PCR
Total RNA was extracted with using TRIzol reagent (Invit-
rogen, Carlsbad, CA) and complementary DNA was syn-
thesized from RNA with the SuperScript™ First-Strand
Synthesis System (Invitrogen, Carlsbad, CA). Polymerase
chain reaction was performed with target-specific primers.
Survivin forward primer: 5' ATGGGTGCCCCGACGTT;
Survivin reverse primer: 5' TCAATCCATGGCAGCCAG;
GAPDH: 5' ACCACAGTCCATGCCATCAC and GAPDH
reverse primer: 5' TCCACCACCCTGTTGCTGTA.
Real-time reverse transcription-polymerase chain reaction 
(Real-time PCR)
Expression level of Survinin transcript was determined by
real-time reverse transcriptase (RT)-polymerase chain
reaction (PCR) using a LightCycler instrument (Roche,
Indianapolis, IN). Primers and Taqman probes were
designed by Probe Finder™ http://www.universal
probelibrary.com. Taqman probes were from the Univer-
sal Probe Library: Survinin [49] and hGAPDH [17]. Spe-
cific primers with following sequences were used:
Survinin forward, 5' GCCCAGTGTTTCTTCTGCTT; Sur-
vivin reverse, 5'CCGGACGAATGCTTTTTATG; hGAPDH
forward, 5' AGCCACATCGCTCAGACAC and hGAPDH
reverse, 5' GCCCAATACGACCAAATCC. The real-time
PCR condition was as follows: 1 cycle of initial denatura-
tion at 95°C for 10 min, 45 cycles of amplification at
95°C for 10 s, 60°C for 30 s, and 72°C for 1 s, with a sin-
gle fluorescence acquisition. GAPDH gene was used as an
internal control.
siRNA
Target-validated siRNA oligos (Santa Cruz Biotechnology,
Santa Cruz, CA) were transfected into cells using the Lipo-
fectamine-2000 reagent (Invitrogen, Carlsbad, CA).
Briefly, cells were seeded onto 96-well plates or chamber-
slides, and cultured overnight in 100 μl of antibiotic-free
RPMI media. siRNA oligomers (8 pmol in 0.4 μl) were
diluted in 25 μl of Opti-MEM® I medium (Invitrogen,
Carlsbad, CA) without serum, and then mixed with 0.2 μl
of Lipofectamine-2000 transfection reagent for 25 min at
room temperature. Cells were overlaid with the transfec-
tion mixture, and incubated for various times.
SDS-PAGE and Western Blot Analysis
Cells were lysed with ice-cold lysis buffer (10 mM Tris, 1
mM EDTA, 1 mM DTT, 60 mM KCl, 0.5% NP-40 and pro-
tease inhibitors). Total cell lysates, fractions of superna-
tant or pellet were resolved on 10% and 12%
polyacrylamide SDS gels under reducing conditions. The
resolved-proteins were electrophoretically transferred to
PVDF membranes (Amersham Life Science, Amersham,
U.K.) for Western blot analysis. The membranes were
blocked with 5% non-fat milk powder at room tempera-
ture for two hours, washed twice with PBST (1% Tween)
and then incubated with primary antibody for 90 minutes
at room temperature. The membranes were washed twice
with PBST then subsequently incubated with a horserad-
ish peroxidase-conjugated secondary antibody (dilution
at 1:10000, Santa Cruz Biotechnology, Santa Cruz, CA).
Immunoreactivity was detected by Enhanced Chemilumi-
nescence (Amersham International, Buckingham, U.K.)
and autoradiography.
MTT cell viability assay
3 × 103 cells in 100 μL of drug-free culturing medium were
seeded onto 96-well plates for 24 hours before treatments.
Cells were then treated with various concentration of
BPR0L075 for 72 hours. 25 μL of MTT (5 mg/mL) was
added into each sample and incubated for 4 hours, under
5% CO2 and 37°C. 100 μL of lysis buffer (20% SDS, 50%
DMF) was subsequently added into each sample and fur-
ther reacted for 16 hours. IC50 value resulting from 50%
inhibition of cell growth was calculated graphically as a
comparison with control growth.
Immunofluorescent microscopy
Cells were cultured in 8-well chamber slides, fixed with
4% paraformaldehyde, and permeabilized with TPBS.
They were incubated with primary antibody for 60 min atMolecular Cancer 2009, 8:43 http://www.molecular-cancer.com/content/8/1/43
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room temperature followed by FITC-conjugated second-
ary antibody. Slides were examined by microscopy using
an Olympus BX50 microscope (Olympus optical co., LTD,
Tokyo, Japan). Images were taken on the Olympus micro-
scope with the use of software CoolSNAP (Roper Scien-
tific, Inc.)
Real-time Caspase-3/-7 activity imaging and caspase-3/-7 
activity assay
Caspase-3/-7 activity was analyzed with a MagicRed™-
DEVD Caspase Detection Kit (Immunochemistry Tech-
nologies LLC, Bloomington, MN). Briefly, cells were cul-
tured in chamber-slides and incubated with test agents.
Cells were then incubated with caspase substrate MR-
(DEVD2) in culture medium for 60 min, and then with
Hoechst 33342 stain for 15 min. Cells were viewed with a
UV-enabled inverted-microscope at an excitation wave-
length of 540 nm – 560 nm and emission at 610 nm.
Quantitative analysis of caspase-3/-7 activity was per-
formed on 96-well plates. Cells were cultured on 96-well
plates and incubated with test agents. Treated-cells were
then incubated with caspase substrate MR-(DEVD2) in
culture medium for 90 min. Caspase-3/-7 activity was
measured with a 96-well plate reader at an excitation
wavelength of 590 nm and emission at 615 nm.
Visualization of apoptosis by the TUNEL assay
Cells were seeded and cultured in 8-well chamber-slides,
and treated with various treatments. The cells were
washed with PBS, fixed with 4% paraformaldehyde for 30
min on ice, and permeabilized with TPBS at room temper-
ature. Apoptotic cells were stained by the TUNEL agent
using an In-Situ Apoptosis Detection TMR Kit (Roche
Diagnostic, Mannheim, Germany). Cells were counter-
stained with DAPI to detect nucleus, and examined by flu-
orescence microscopy.
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